Abstract
Diabetic patients have higher BMD but greater risk for fragility fractures than do nondiabetics. Could diabetes medications account for this finding? In two studies, researchers investigated whether thiazolidinediones (TZDs) were linked to elevated fracture incidence. In the original A Diabetes Outcome Progression Trial (ADOPT) — a comparison of the glucose-controlling effects of rosiglitazone (a TZD), glyburide, and metformin — a relatively high rate of fractures among rosiglitazone users was identified unexpectedly. In a supplementary …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
